Earnings Call Summary | Tenon Medical(TNON.US) Q1 2024 Earnings Conference
Earnings Call Summary | Tenon Medical(TNON.US) Q1 2024 Earnings Conference
The following is a summary of the Tenon Medical, Inc. (TNON) Q1 2024 Earnings Call Transcript:
以下是Tenon Medical, Inc.（TNON）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Tenon Medical reported Q1 2024 revenue of $719,000, a 66% increase from the same period last year driven by a 42% rise in surgical procedures utilizing Catamaran system.
Operating losses decreased from $4.9 million in Q1 2023 to $3.5 million in Q1 2024 due to cuts in research and development expenses and third-party sales and marketing expenses.
The company managed to generate $2.6 million from a preferred stock raise in Q1 2024 and retire $1.25 million in secured debt from the previous quarter, ending with no outstanding debt as of March 31, 2024.
Tenon Medical報告稱，2024年第一季度收入爲71.9萬美元，比去年同期增長了66％，這要歸因於使用雙體船系統的外科手術增長了42％。
由於研發費用以及第三方銷售和營銷費用削減，營業虧損從2023年第一季度的490萬美元減少到2024年第一季度的350萬美元。
該公司設法在2024年第一季度通過優先股籌集了260萬澳元，並償還了上一季度的125萬美元有擔保債務，截至2024年3月31日沒有未償債務。
Business Progress:
業務進展：
Tenon Medical begins its second year of commercialization, with continual advancements and broadening the competitive field with their proprietary Catamaran system.
They are set to increase their marketing, promotion, and workshop efforts as they have conducted more than 500 surgeries with the Catamaran system, showing an exceptional safety profile.
Kristine Jacques has been welcomed to the Board of Directors, and the patent portfolio for the Catamaran system expanded.
Tenon Medical開始了其商業化的第二年，憑藉其專有的雙體船系統不斷進步並擴大了競爭領域。
他們已經使用雙體船系統進行了500多次手術，表現出卓越的安全性，因此將加大營銷、推廣和研討會的力度。
克里斯汀·雅克受到了董事會的歡迎，雙體船系統的專利組合也得到了擴大。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。